Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 73636 - Advisory Committee on Breast Cancer in Young Women - Statutory (Congress Created)


Committee NameAdvisory Committee on Breast Cancer in Young WomenAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number73636
Original Establishment Date6/17/2010Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*38
Current Charter Date6/17/2020Designated Fed Officer Position Title*Public Health Analyst
Date Of Renewal Charter6/17/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Kimberly
Exempt From Renewal*NoDesignated Federal Officer Middle NameE.
Specific Termination AuthorityDesignated Federal Officer Last Name*Smith
Establishment Authority*Statutory (Congress Created)Designated Federal Officer Suffix
Specific Establishment Authority*Section 399NN of the of the Public Health Service ActDesignated Federal Officer Phone*(404) 498-0073
Effective Date Of Authority*3/23/2010Designated Federal Officer Fax*(770) 488-4760
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Other Committee


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The committee is authorized to recommend evidence-based initiatives for the purposes of advancing understanding and awareness of breast cancer among young women (particularly those at heightened risk for developing breast cancer); to establish and conduct public and health care professional education activities; to conduct prevention research; and to support the dissemination of evidence-based age appropriate messages and materials.
How is membership balanced?*Membership includes expertise in the fields of breast cancer, prevention, early detection, diagnosis, public health, social marketing, genetic testing and counseling, treatment, rehabilitation, palliative care, and survivorship or in related disciplines with a specific focus on young women. The committee also includes ex-officio representatives from the National Cancer Institute; Department of Defense; Indian Health Service; Agency for Healthcare Research and Quality; Health Resources and Services Administration; and the US Department of Health and Human Services, Office of Women's Health. The committee has three ethnic/racial minority representatives and thirteen females
How frequent & relevant are cmte mtgs?*Meetings are held one to two times per year, which are relevant to items outlined in the committee's charter. This includes establishing and conducting public and health care professional education activities, conducting prevention research, and supporting the dissemination of evidence-based age appropriate messages and materials. However, if the need arises, the committee will convene a meeting to meet the needs of the committee/agency.
Why advice can't be obtained elsewhere?*The Advisory Committee on Breast Cancer in Young Women shall provide advice and guidance to the Secretary, HHS, the Assistant Secretary for Health, and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.
Why close or partially close meetings?N/A
Recommendation RemarksThis committee does not generate formal reports. The committee met once in FY22. No recommendations were made. Ex-Officio Camille Fabiyi resigned 8/31/2022.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionNoAction CommentCDC launched and completed formative research regarding the national public education campaign targeting young women and health care providers about early onset breast cancer and general breast health among young women. The public education campaign was also launched in May 2015 and is ongoing. Information can be found at
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentN/ANumber Of Grants Recommended0
Cost Savings*NoneDollar Value Of Grants Recommended$0.00
Cost Savings CommentNot ApplicableGrants Review CommentN/A
Number Of Recommendations*26Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentNo formal recommendations were made in FY22. There were 14 formal recommendations in FY21. There were 9 formal recommendations in FY15 and 3 formal recommendations in FY14 for a total of 26 recommendations for the life of the committee.Access Agency WebsiteYes
% of Recs Fully Implemented*50.00%Access Committee WebsiteYes
% of Recs Fully Implemented Comment13 of 26 recommendations have been fully implemented. They include FY15 Recommendations #1-4, #6, #8-9, all FY14 Recommendations 1-3, FY21 Recommendations #2, #5, & #9. In FY21, FY15 Recommendation #8 and FY21 Recommendation #9 have both been completed with the implementation of Continuing Medical Education (CMEs) through Medscape and ACOG. In FY20: FY14 Recommendation #2, FY15 Recommendations #6, & #9 which address Patient & Provider communication were completed. CDC funded an effort to identify important health messages and resources needed to facilitate patient/provider dialogue regarding early breast cancer in FY17. In FY18, a Breast Health Education Evaluation occurred where CDC funded a contract to evaluate existing programs which educate Health Care Providers (HCPa) about HBOC and early onset breast cancer. The project was completed and deployed to the public in FY20. Two Continuing Medical Education (CME) Modules including The Educating Medical Providers about Breast Cancer in Young Women: Breast Cancer Risk Factors, Survivorship, and Breast Health contract awarded in FY15 and released in FY17 and The Understanding Early Onset Breast Cancer CME Module in FY20 address FY15 Recommendations #6,#8,#9 & FY14 Recommendation #3. Additionally, in FY20 a Risk Assessment Tool was created and is now available to health care providers on the CDC Division of Cancer Prevention and Control website. Also, resources have been developed for providers and consumers about Direct to Consumer Genetic Testing which has aided in the completion of FY21 Recommendation #8.
CDC continues to expand upon the Bring Your Brave (BYB) Campaign which was most recently funded in FY21-FY25. Bring Your Brave is a large social/digital media campaign launched in 2015 to provide information about breast cancer to women younger than age 45. The campaign tells real stories about young women whose lives have been affected by breast cancer. These stories about prevention, risk, family history and survivorship bring to life the idea that young women can be personally affected by breast cancer. Through these testimonials, Bring Your Brave aims to inspire young women to learn their risk for breast cancer, talk with their health care provider about their risk, and live a breast healthy lifestyle. The FY21 contract focused primarily on HCP education and communication with young women. A project to develop additional video-based training resources for HCPs was funded through the CDC Center for State, Tribal, Local, and Territorial Support (CSTLTS) in FY18 and was completed in FY20.
In FY17 CDC implemented the following efforts with regard to recommendations 6 & 8: Doc Styles Survey: CDC implemented a survey about early onset breast cancer and provider behavior on the Doc Styles survey. Data collection was completed in June 2017 and analysis is complete. Bring Your Brave formative research: CDC implemented multiple rounds of formative research to engage with Heath Care Providers (HCPs) regarding their breast cancer education needs and resources; findings resulted in the development of a CME and various digital resources and web pages; Know: BRCA evaluation: engaged HCPs in qualitative research efforts to learn more about their needs and utilization of resources related to hereditary breast and ovarian cancer (HBOC).
FY15 Recommendation #5 is supported in part through various DCPC research projects (i.e. genomics, alcohol, etc. The Know: BRCA (formerly BodyTalk) clinical decision support tool was launched in 2014 to address issues of hereditary breast cancer among young women. The resource includes content that encourages health care providers and young women to engage in dialogue about breast cancer risk. The resource was evaluated and completed in FY18 for efficacy and utilization. As a result of the evaluation Know: BRCA/Body Talk was modified to address issues identified in the evaluation in FY21 and it was relaunched to reflect the changes. It is now branded as the My Family Health Portrait: Cancer App (MFHP:Cancer), currently available for Android devices. The IOS device app is in the works.
Additional continued activities include funding grantees to support young breast cancer survivors and increase knowledge about breast cancer genetics and the use of the Know: BRCA clinical decision support tool. In FY20 a cooperative agreement was launched which focuses on supporting young breast cancer survivors including metastatic and underserved populations. The development of provider resources and patient navigation resources is also a part of this ongoing work which addresses FY15 Recommendation #9.
Access GSA FACA WebsiteYes
% of Recs Partially Implemented*4.00%Access PublicationsNo
% of Recs Partially Implemented Comment1 of 26 recommendations have been partially implemented. FY21 Recommendation #8 is approximately 25% complete. The task is to develop simple, supplemental provider educational resources to address gaps in content and the DCIS and DTC genetic testing components have been complete. 12 of 26 recommendations have not been implemented (46.2%). A portion of these recommendations are under consideration for implementation and a portion are out of scope and will not be implemented.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*CDC provides feedback to the Committee during formal public meetings.Narrative Description*The Advisory Committee on Breast Cancer in Young Women provides advice and guidance to the Secretary, HHS, the Assistant Secretary for Health, and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.
Hide Section - COSTS


Payments to Non-Federal Members*$2,750.00Est Payments to Non-Fed Members Next FY*$11,250.00
Payments to Federal Members*$2,028.00Est. Payments to Fed Members Next FY*$10,138.00
Payments to Federal Staff*$93,040.00Estimated Payments to Federal Staff*$97,319.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$19,407.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$1,427.00
Other Costs$4,519.00Est. Other Costs Next FY*$7,467.00
Total Costs$102,337.00Est. Total Next FY*$147,008.00
Date Cost Last Modified11/2/2022 6:33 AMEst. Fed Staff Support Next FY*0.60
Federal Staff Support (FTE)*0.60Est Cost Remarks
Cost RemarksTo comply with §2(b)(5) of the FACA, the Federal Management Regulation (FMR Bulletin 2022-F1) requires agencies report all costs of committee activities, including FRN notices for the operation of a committee.  
Hide Section - Interest Areas

Interest Areas

Applied Science
Applied Sciences
Basic Science
Basic Sciences
Civil Rights
Native Americans
Broadcasting and Communications
Health Care
Medical Education
Medical Practitioners
Public Health
Research and Statistics
Health and Health Research
Medicine and Dentistry
Rehabilitation and Disability
Basic Research
Research and Development
Research and Statistics
Social Sciences
Risk Communication


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-040451Advisory Committee on Breast Cancer in Young Women2021
 COM-038726Advisory Committee on Breast Cancer in Young Women2020
 COM-036609Advisory Committee on Breast Cancer in Young Women2019
 COM-034813Advisory Committee on Breast Cancer in Young Women2018
 COM-002026Advisory Committee on Breast Cancer in Young Women2017
 COM-002546Advisory Committee on Breast Cancer in Young Women2016
 COM-004169Advisory Committee on Breast Cancer in Young Women2015
 COM-004471Advisory Committee on Breast Cancer in Young Women2014
 COM-006291Advisory Committee on Breast Cancer in Young Women2013
 COM-006497Advisory Committee on Breast Cancer in Young Women2012
 COM-008329Advisory Committee on Breast Cancer in Young Women2011
 COM-008704Advisory Committee on Breast Cancer in Young Women2010